X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (94) 94
index medicus (94) 94
infectious diseases (88) 88
adult (82) 82
female (82) 82
male (81) 81
hiv (65) 65
hiv infections - drug therapy (64) 64
human immunodeficiency virus--hiv (52) 52
antiretroviral therapy (51) 51
immunology (50) 50
middle aged (50) 50
thailand (45) 45
virology (43) 43
aids/hiv (35) 35
antiretroviral drugs (31) 31
hiv infection (31) 31
hiv infections - complications (31) 31
viral load (31) 31
acquired immune deficiency syndrome--aids (26) 26
drug therapy (25) 25
antiviral agents (24) 24
pharmacology & pharmacy (24) 24
tenofovir (24) 24
hiv infections - virology (23) 23
antiretroviral therapy, highly active (22) 22
highly active antiretroviral therapy (22) 22
microbiology (21) 21
virus diseases (21) 21
aids (20) 20
anti-hiv agents - therapeutic use (20) 20
cd4 antigen (20) 20
cd4 lymphocyte count (20) 20
hiv-infected patients (20) 20
adults (19) 19
asia (18) 18
health aspects (17) 17
mortality (17) 17
treatment outcome (17) 17
analysis (16) 16
hiv infections - immunology (16) 16
infected patients (16) 16
infection (16) 16
prospective studies (16) 16
protease inhibitors (16) 16
research (16) 16
tuberculosis (16) 16
anti-hiv agents - administration & dosage (15) 15
efavirenz (15) 15
emtricitabine (15) 15
risk factors (15) 15
ritonavir (15) 15
therapy (15) 15
young adult (15) 15
cross-sectional studies (14) 14
patients (14) 14
prevalence (14) 14
active antiretroviral therapy (13) 13
antiretroviral agents (13) 13
article (13) 13
disoproxil fumarate (13) 13
human-immunodeficiency-virus (13) 13
thailand - epidemiology (13) 13
aged (12) 12
anti-hiv agents - pharmacokinetics (12) 12
care and treatment (12) 12
clinical trials (12) 12
efficacy (12) 12
ribonucleic acid--rna (12) 12
studies (12) 12
viruses (12) 12
dosage and administration (11) 11
lopinavir (11) 11
pharmacokinetics (11) 11
research article (11) 11
risk (11) 11
antiretroviral therapy, highly active - methods (10) 10
coinfection (10) 10
drug therapy, combination (10) 10
hiv infections - blood (10) 10
hiv infections - epidemiology (10) 10
infectious disease (10) 10
medicine (10) 10
regression analysis (10) 10
risk-factors (10) 10
usage (10) 10
adolescent (9) 9
anti-retroviral agents - therapeutic use (9) 9
diagnosis (9) 9
drug resistance (9) 9
drugs (9) 9
hiv patients (9) 9
hiv-1 (9) 9
hiv-1-infected patients (9) 9
plasma (9) 9
prevention (9) 9
ritonavir - administration & dosage (9) 9
safety (9) 9
statistical analysis (9) 9
cohort studies (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2014, Volume 67, p. S99
  Asia is seeing a rise in noncommunicable diseases in their general population and among people living with HIV. Many Asians have low body weight, which can... 
Genotype & phenotype | Acquired immune deficiency syndrome--AIDS | Toxicity | Human immunodeficiency virus--HIV | Metabolism | Cancer
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2014, Volume 67, pp. S99 - S99
Asia is seeing a rise in noncommunicable diseases in their general population and among people living with HIV. Many Asians have low body weight, which can... 
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 2015, Volume 9, pp. 5763 - 5769
This article is to provide an update overview of cobicistat (COBI)-boosted darunavir in response to its recent approval by the US Food and Drug Administration,... 
Pharmacoenhancer | Tolerability | First-line regime | Adverse events | Ritonavir | Drug–drug interactions | CHEMISTRY, MEDICINAL | first-line regime | adverse events | SINGLE AGENTS | HUMAN-IMMUNODEFICIENCY-VIRUS | HIV-INFECTED PATIENTS | drug-drug interactions | TREATMENT-NAIVE | pharmacoenhancer | ritonavir | tolerability | DISOPROXIL FUMARATE | PHARMACOLOGY & PHARMACY | FIXED-DOSE COMBINATION | HEALTHY-VOLUNTEERS | ONCE-DAILY DARUNAVIR/RITONAVIR | BOOSTED PROTEASE INHIBITORS | HIV Protease Inhibitors - adverse effects | Darunavir - pharmacokinetics | Food-Drug Interactions | HIV Infections - virology | Humans | Risk Factors | Treatment Outcome | HIV Protease Inhibitors - therapeutic use | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | HIV Infections - diagnosis | Cobicistat - adverse effects | HIV Infections - drug therapy | Darunavir - adverse effects | Cobicistat - therapeutic use | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Darunavir - therapeutic use | Drug Combinations | Darunavir | Patient outcomes | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Methods | Cytochrome | Lipids | Dosage | Proteins | Acquired immune deficiency syndrome--AIDS | Protease | Antiretroviral agents | Human immunodeficiency virus--HIV | Antiviral activity | Drug interaction | Drug dosages | Food | Cytochromes P450 | Creatinine | Antiretroviral drugs | Enzymes | Hyperlipidemia | Cytochrome P450 | Drug interactions | Pharmacology | Proteinase inhibitors | FDA approval | Metabolism | Insulin | Patients | Glomerular filtration rate | Inhibitors | Lipodystrophy | Binding sites
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 9, pp. 795 - 807
Journal Article
WORLD JOURNAL OF GASTROENTEROLOGY, ISSN 1007-9327, 09/2019, Volume 25, Issue 35, pp. 5388 - 5402
BACKGROUND Abnormal liver chemistry is a common problem in human immunodeficiency virus (HIV)-infected patients. Common causes of abnormal liver enzymes in... 
Liver biopsy | Autoimmunity | CRITERIA | ANTIBODIES | DIAGNOSIS | PREVALENCE | Antiretroviral therapy | FEATURES | Immunosuppression | Case report | INTERFERON | Autoimmune hepatitis | HIV-INFECTION | THERAPY | NATIONWIDE | Human immunodeficiency virus | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Case Report
Journal Article
Journal of the International AIDS Society, ISSN 1758-2652, 06/2019, Volume 22, Issue 6, pp. e25334 - n/a
The letter notes that the sensitivity of the screening tests used in our study differed substantially, and the author of the letter favoured haemoglobin A1c... 
viral suppression | screening | Asia‐Pacific | HIV | diabetes | Studies | Glucose | Diabetes
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 4, p. e0154221
Journal Article
PHARMACOGENOMICS, ISSN 1462-2416, 05/2019, Volume 20, Issue 7, pp. 517 - 527
Aim: To evaluate the influence of genetic polymorphisms on plasma trough concentrations of atazanavir (ATV) and ritonavir (RTV). Patients & methods: The... 
GENETIC POLYMORPHISMS | RECEPTOR PXR | CYP3A5 6986A > G | LOPINAVIR | polymorphisms | PROTEASE INHIBITORS | RITONAVIR-BOOSTED ATAZANAVIR | plasma concentrations | UNBOOSTED ATAZANAVIR | ANTIRETROVIRAL DRUGS | IMPACT | PHARMACOKINETICS | atazanavir | PLASMA-CONCENTRATIONS | ritonavir | SLCO1B1 521T > C | PHARMACOLOGY & PHARMACY
Journal Article
Sexually Transmitted Infections, ISSN 1368-4973, 06/2017, Volume 93, Issue Suppl 1, p. A41
IntroductionElvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate(E/C/F/TDF) demonstrated superior efficacy when compared with atazanavir boosted... 
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 09/2017, Volume 32, Issue 9, pp. 1945 - 1955
ABSTRACT Both HIV infection and antiretroviral therapy (ART) are associated with lower bone mineral density (BMD) and increased fracture risk. Because the... 
ANTIRETROVIRAL THERAPY | BONE MINERAL DENSITY | HIV | DXA | CLINICAL TRIALS | ABACAVIR-LAMIVUDINE | EMTRICITABINE | ADULTS | RISK | BODY-COMPOSITION | PREVALENCE | NAIVE | OSTEOPOROSIS | FRACTURE | TENOFOVIR DISOPROXIL FUMARATE | ENDOCRINOLOGY & METABOLISM | HIV Infections - diagnostic imaging | HIV-1 | Lumbar Vertebrae - metabolism | Lumbar Vertebrae - diagnostic imaging | Humans | Anti-Retroviral Agents - adverse effects | Male | Absorptiometry, Photon | Fractures, Bone - metabolism | Bone Resorption - diagnostic imaging | Bone Density - drug effects | Anti-Retroviral Agents - administration & dosage | Bone Resorption - metabolism | Adult | Female | HIV Infections - drug therapy | Bone Resorption - chemically induced | Fractures, Bone - diagnostic imaging | Fractures, Bone - chemically induced | HIV Infections - metabolism | Highly active antiretroviral therapy | Antiviral agents | Care and treatment | AIDS treatment | Analysis | Bones | HIV (Viruses) | Health aspects | HIV infection | Density | Dual energy X-ray absorptiometry | Spine (lumbar) | Clinical trials | Regression analysis | Efavirenz | Hip | Antiretroviral therapy | CD4 antigen | Tenofovir | Human immunodeficiency virus--HIV | Hormone replacement therapy | Bone mineral density | Bone density | Bone loss | Drug therapy | Bone Mineral Density | Clinical Trials
Journal Article